A Phase 1, Open-label Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of PF-07328948 Following Multiple Oral Doses in Healthy Chinese Adult Participants
Latest Information Update: 26 Mar 2026
At a glance
- Drugs PF 07328948 (Primary)
- Indications Heart failure
- Focus Pharmacokinetics
- Sponsors Pfizer
Most Recent Events
- 23 Mar 2026 Planned End Date changed from 3 May 2026 to 15 Apr 2026.
- 23 Mar 2026 Planned primary completion date changed from 3 May 2026 to 15 Apr 2026.
- 23 Mar 2026 Status changed from not yet recruiting to active, no longer recruiting.